Kaiser Foundation Hospitals and Medpace took part in a round that will support phase 3 trials for the startup's lead cardiometabolic disease drug candidate.

The behavioural health assistance platform will get a public listing through the deal, which follows $110m from investors including SoftBank.

Illumina Ventures and AV8 Ventures returned for a series A round that will push the startup's liquid biopsy technology towards the clinical trial stage.

Lundbeck and Novo were among the participants in the immuno-oncology drug developer's series B round having backed its series A four years ago.

The Minth Group, Zoll Medical and Abiomed-backed medical device developer has raised at least $217m in total after closing additional series D funding.

Pfizer's Breakthrough Growth Initiative has backed the PureTech microbiome spinoff, which will use the cash to finance phase 2 tests of its lead IBD drug candidate.

The book publisher and nursing care service group’s Gakken Innovation-Tech Fund plans to invest about $29m over the next five years, targeting edtech and healthtech.

Heska has agreed to buy the R/GA-backed veterinary telemedicine platform developer in a deal set to close later this quarter.

GlaxoSmithKline has exited the CDS platform operator, which has been purchased by patient care software provider Amalgam Rx for an undisclosed sum.

Echo Health Ventures has joined Arkansas Blue Cross Blue Shield's investment arm in a strategic initiative aimed at scaling up healthcare businesses.